Table 2

Inhibition of fibrinogen binding to human recombinant WT αIIbβ3 and to recombinant human αIIbβ3 containing a chimeric human/rat α subunit by echistatin and eristostatin

WT human αIIbβ3Human αIIbβ3 + αIIb D232HHuman αIIbβ3 + rat αIIb W3:4-1/W4:4-1
IC50 for inhibiting fibrinogen binding to αIIbβ3, nM*    
    Echistatin 29.2 298.9 1.09 × 106 
    Erisostatin 100.9 283.1 5.23 × 104 
Relative IC50 for inhibiting fibrinogen binding to αIIbβ3    
    Echistatin 10.2 3.7 × 104 
    Erisostatin 2.8 519 
WT human αIIbβ3Human αIIbβ3 + αIIb D232HHuman αIIbβ3 + rat αIIb W3:4-1/W4:4-1
IC50 for inhibiting fibrinogen binding to αIIbβ3, nM*    
    Echistatin 29.2 298.9 1.09 × 106 
    Erisostatin 100.9 283.1 5.23 × 104 
Relative IC50 for inhibiting fibrinogen binding to αIIbβ3    
    Echistatin 10.2 3.7 × 104 
    Erisostatin 2.8 519 
*

IC50 were calculated from the equations from the trend lines shown in Figure 4.

IC50 were normalized to fibrinogen binding to wild-type human αIIbβ3.

Close Modal

or Create an Account

Close Modal
Close Modal